[1] A E MUTLIB. Characterization of metabolites of xylazine produced in vivo and in vitro by LC/MS/MS and by GC/MS.[J]. Drug Metabolism and Disposition, 1992, 20 6: 840-848.
[2] M.-H. SPYRIDAKI . Determination of xylazine and its metabolites by GC–MS in equine urine for doping analysis[J]. Journal of pharmaceutical and biomedical analysis, 2004, 35 1: Pages 107-116. DOI:
10.1016/j.jpba.2003.12.007[3] W. H. KWOK. Screening of over 100 drugs in horse urine using automated on-line solid-phase extraction coupled to liquid chromatography-high resolution mass spectrometry for doping control.[J]. Journal of Chromatography A, 2017, 44 1: 89-101. DOI:
10.1016/j.chroma.2017.02.020[4] RAIMO VIRTANEN . Characterization of the selectivity, specificity and potency of medetomidine as an α2-adrenoceptor agonist[J]. European journal of pharmacology, 1988, 150 1: Pages 9-14. DOI:
10.1016/0014-2999(88)90744-3[5] CLAIRE A RICHARDSON Paul A F. Anaesthesia and post-operative analgesia following experimental surgery in laboratory rodents: are we making progress?[J]. Atla-Alternatives To Laboratory Animals, 2005, 33 2: 119-127. DOI:
10.1177/026119290503300207[6] DVM A V, DVSC. Alpha-2 Agonists as Pain Therapy in Horses[J]. Veterinary Clinics of North America-Equine Practice, 2010, 26 3: Pages 515-532. DOI:
10.1016/j.cveq.2010.07.003 
